Amgen’s Krypolis fails newly diagnosed multiple myeloma study
(Reuters) – Amgen Inc said on Tuesday its multiple myeloma drug, Kyprolis, was not found superior to Takeda Pharmaceutical Co Ltd's Velcade in a late-stage study in previously untreated patients. The U.S. Food and Drug Administration has already approved Kyprolis for patients with relapsed or refractory multiple myeloma who have previously undergone one or more treatments. The latest study tested a regimen of Krypolis against Velcade in patients who also received the chemothereutic agent melphalan and the immunosuppressant prednisone, and were deemed ineligible for stem-cell transplants.
